Biosimilars in Rheumatology: Current Perspectives and Lessons Learnt

Overview

Journal Nat Rev Rheumatol

Specialty Rheumatology

Date 2015 Aug 19

PMID 26282080

Citations 40

Authors

Thomas Dorner

Jonathan Kay

Affiliations

Soon will be listed here.

Abstract

Biosimilars, based on biopharmaceuticals approved by regulatory agencies that are no longer under patent protection, have efficacy and safety comparable to their reference products, and are a new therapeutic option to treat inflammatory diseases. Biosimilars must be distinguished from 'biomimics' or 'biocopies', which are marketed in some countries but have not been evaluated according to the stringent regulatory pathway used for biosimilars. CT-P13, based on infliximab, was the first biosimilar approved for the treatment of inflammatory diseases; however, some countries did not allow extrapolation of indications to all eight diseases for which the reference drug infliximab is approved. Antidrug antibodies can reduce drug levels and affect clinical efficacy, but although available data suggest that biosimilars and their reference products have comparable immunogenicity, this important property might differ between individual biopharmaceuticals. This Review discusses biosimilars already approved within the past 3 years to treat rheumatic diseases, as well as others that are currently under development. The main challenges posed by biosimilars are also addressed, such as the extrapolation of indications to diseases only studied for the reference drug, and the definition of strategies for adequate pharmacovigilance to monitor biosimilars after marketing approval.

Citing Articles

Efficacy and Safety of CT-P13 as First- and Second-Line Treatment in Patients with Ankylosing Spondylitis.

Uslu S, Gulle S, Sen G, Capar S, Senel S, Dalkilic E J Clin Med. 2024; 13(23).

PMID: 39685726 PMC: 11642210. DOI: 10.3390/jcm13237266.

An Overview of Adalimumab Therapy for Ankylosing Spondylitis.

Sukhanova A, Gilavian M, Melnik E, Shikh E, Petukhov A, Gegechkori V Curr Rheumatol Rev. 2024; 20(5):501-513.

PMID: 38415452 PMC: 11340288. DOI: 10.2174/0115733971289295240223095751.

Network pharmacology-based strategy to investigate the bioactive ingredients and molecular mechanism of Evodia rutaecarpa in colorectal cancer.

Lu Y, Dong K, Yang M, Liu J BMC Complement Med Ther. 2023; 23(1):433.

PMID: 38041080 PMC: 10691004. DOI: 10.1186/s12906-023-04254-8.

Extracts of inhibit SARS-CoV-2 and inflammation .

Ma J, Wei J, Chen G, Yan X, Sun H, Li N Pharm Biol. 2023; 61(1):1446-1453.

PMID: 37675874 PMC: 10486283. DOI: 10.1080/13880209.2023.2253841.

An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review.

Hariprasad S, Gale R, Weng C, Ebbers H, Rezk M, Tadayoni R Ophthalmol Ther. 2022; 11(3):959-982.

PMID: 35278204 PMC: 9114261. DOI: 10.1007/s40123-022-00488-w.

References

Danese S, Fiorino G, Michetti P . Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization. J Crohns Colitis. 2014; 8(11):1548-50. DOI: 10.1016/j.crohns.2014.06.007. View

Fiorino G, Danese S . The biosimilar road in inflammatory bowel disease: the right way?. Best Pract Res Clin Gastroenterol. 2014; 28(3):465-71. DOI: 10.1016/j.bpg.2014.04.006. View

Mazilu D, Opris D, Gainaru C, Iliuta M, Apetrei N, Luca G . Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment. Biomed Res Int. 2014; 2014:702701. PMC: 4054977. DOI: 10.1155/2014/702701. View

Mok C, van der Kleij D, Wolbink G . Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases. Clin Rheumatol. 2013; 32(10):1429-35. DOI: 10.1007/s10067-013-2336-x. View

Castaneda-Hernandez G, Szekanecz Z, Mysler E, Azevedo V, Guzman R, Gutierrez M . Biopharmaceuticals for rheumatic diseases in Latin America, Europe, Russia, and India: innovators, biosimilars, and intended copies. Joint Bone Spine. 2014; 81(6):471-7. DOI: 10.1016/j.jbspin.2014.03.019. View

Gecse K, Khanna R, van den Brink G, Ponsioen C, Lowenberg M, Jairath V . Biosimilars in IBD: hope or expectation?. Gut. 2013; 62(6):803-7. DOI: 10.1136/gutjnl-2012-303824. View

Yoo D, Hrycaj P, Miranda P, Ramiterre E, Piotrowski M, Shevchuk S . A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis. 2013; 72(10):1613-20. PMC: 3786641. DOI: 10.1136/annrheumdis-2012-203090. View

Curtis J, Jain A, Askling J, Bridges Jr S, Carmona L, Dixon W . A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010; 40(1):2-14.e1. PMC: 2958101. DOI: 10.1016/j.semarthrit.2010.03.003. View

Schreiber S, Luger T, Mittendorf T, Mrowietz U, Muller-Ladner U, Schroder J . [Evolution of biologicals in inflammation medicine--biosimilars in gastroenterology, rheumatology and dermatology]. Dtsch Med Wochenschr. 2014; 139(47):2399-404. DOI: 10.1055/s-0034-1387371. View

10.

Aringer M, Dorner T . [Biosimilars : Current state of the build up to series production]. Z Rheumatol. 2013; 72(9):873-7. DOI: 10.1007/s00393-013-1140-y. View

11.

Fiorino G, Girolomoni G, Lapadula G, Orlando A, Danese S, Olivieri I . The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev. 2014; 13(7):751-5. DOI: 10.1016/j.autrev.2014.02.004. View

12.

. The INN crowd. Nat Biotechnol. 2013; 31(12):1055. DOI: 10.1038/nbt.2760. View

13.

DHaens G, Sartor R, Silverberg M, Petersson J, Rutgeerts P . Future directions in inflammatory bowel disease management. J Crohns Colitis. 2014; 8(8):726-34. DOI: 10.1016/j.crohns.2014.02.025. View

14.

Yi S, Kim S, Park M, Yoon S, Cho J, Lim K . Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel®): a double-blind, single-dose, crossover study in healthy volunteers. BioDrugs. 2012; 26(3):177-84. DOI: 10.2165/11631860-000000000-00000. View

15.

Pineda C, Caballero-Uribe C, de Oliveira M, Lipszyc P, Lopez J, Mataos Moreira M . Recommendations on how to ensure the safety and effectiveness of biosimilars in Latin America: a point of view. Clin Rheumatol. 2015; 34(4):635-40. PMC: 4365179. DOI: 10.1007/s10067-015-2887-0. View

16.

Dorner T, Strand V, Castaneda-Hernandez G, Ferraccioli G, Isaacs J, Kvien T . The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis. 2012; 72(3):322-8. DOI: 10.1136/annrheumdis-2012-202715. View

17.

Scheinberg M, Kay J . The advent of biosimilar therapies in rheumatology--"O brave new world". Nat Rev Rheumatol. 2012; 8(7):430-6. DOI: 10.1038/nrrheum.2012.84. View

18.

Kawalec P, Mikrut A, Wisniewska N, Pilc A . Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis. Arch Med Sci. 2013; 9(5):765-79. PMC: 3832823. DOI: 10.5114/aoms.2013.38670. View

19.

Azevedo V, Galli N, Kleinfelder A, DIppolito J, Urbano P . Etanercept biosimilars. Rheumatol Int. 2014; 35(2):197-209. PMC: 4308636. DOI: 10.1007/s00296-014-3080-5. View

20.

Emery P, Vencovsky J, Sylwestrzak A, Leszczynski P, Porawska W, Baranauskaite A . A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy. Ann Rheum Dis. 2015; 76(1):51-57. PMC: 5264222. DOI: 10.1136/annrheumdis-2015-207588. View